A Phase 2 interventional study of Docetaxel and Ramucirumab DP in Carcinoma of Urinary Tract, Urethral Carcinoma and Carcinoma of Ureter, sponsored by Eli Lilly and Company. Completed at 32 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-09.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Urethral Neoplasms with a site in United States — 4 open to participants now, 17 under way, 1 of them phase 3. Urethral Neoplasms · United States.
Among the 76 studies in Urethral Neoplasms with a site in United States, this one is the 14th largest by enrollment of the 69 interventional ones that give a count, is one of 4 that started in 2011, is one of 39 in phase 2, and was the 40th registered.
95 studies on the registry are indexed under Urethral Neoplasms; 5 are open to participants now.
Browse Urethral Neoplasms studies →4 of the 76 studies in Urethral Neoplasms with a site in United States are open now. Recruiting first, the newest first:
AstraZeneca · Sites in United States
Ages 18–130
Rahul Aggarwal · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
Ages 18+
University of Nebraska · Sites in United States
Ages 19–110 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 Urethral Neoplasms studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 42 · Phase 3 7
First in 1995; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 148 is above the median of 44 across 87 interventional studies indexed under Urethral Neoplasms.
Median enrollment 44 across the 69 interventional studies, 58 across the 4 observational. Of the 59 that completed or were terminated, 25 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 76 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 3 studies filed under Urethral Neoplasms — fewer than ten, so there is no comparison to draw.
7 of the studies in Urethral Neoplasms with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03291028Fox Chase Cancer CenterAnalysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma | 2026-12 |
| NCT04963153National Cancer Institute (NCI)Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy | 2026-12-01 |
| NCT04953104M.D. Anderson Cancer CenterARID1A and/or KDM6A Mutation and CXCL13 Expression | 2026-12-31 |
| NCT05888532Rahul Aggarwal64Cu-GRIP B in Patients With Advanced Malignancies | 2026-12-31 |
| NCT03866382National Cancer Institute (NCI)Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | 2027-02-28 |
Add all 7 to your calendar (.ics) → With an account.
Among the 76 studies in Urethral Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This multicenter trial will enroll participants with metastatic transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis who have had disease progression on first-line platinum-based chemotherapy regimens. Participants will be enrolled into 1 of 3 treatment arms: docetaxel; docetaxel and ramucirumab; or docetaxel and icrucumab.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Does not have:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.
Drug: Docetaxel
Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.
Drug: Docetaxel · Biological: Ramucirumab DP
Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.
Drug: Docetaxel · Biological: Icrucumab
Docetaxel: 75 milligram/square meter (mg/m2) on Day 1 of each 21-day cycle
Ramucirumab (DP): 10 milligram/kilogram (mg/kg) intravenous (IV) on day 1 of each 21-day cycle
Also known as: IMC-1121B, LY3009806
12 mg/kg I.V. on day 1 and Day 8 of each 21-day cycle
Also known as: IMC-18F1, LY3012212
Progression-Free Survival (PFS)
PFS time was the time from randomization until the date of objectively determined progressive disease (PD) or death due to any cause, whichever occurred first. According to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), PD was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the 20% relative increase, the sum must have also demonstrated an absolute increase of at least 5 millimeters (mm). The appearance of 1 or more new lesions and/or unequivocal progression of existing nontarget lesions was also considered progression. Participants without objectively determined PD who were alive at the end of the follow-up period (or lost to follow-up) were censored on the date of the participant's last complete radiographic tumor assessment; if no baseline or post-baseline radiologic assessment was available, the participant was censored at the date of randomization.
Time frame: Randomization to Measured PD or Death From Any Cause (Up To 40 Months)
Percentage of Participants Achieving Objective Response Rate (ORR)
Participants achieved an objective response if they had a best overall response of partial response (PR) or complete response (CR). According to RECIST v1.1, PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter; CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \<10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels \[if tumor markers were initially above the upper limit of normal (ULN)\]. The percentage of participants who achieved an objective response=(number of participants with CR or PR)/(number of participants assessed)\*100.
Time frame: Randomization to Measured PD (Up to 40 Months)
Duration of Response
The duration of response was measured from the time measurement criteria were first met for a CR or PR (whichever was first recorded) until the first date of objectively documented progressive disease (taking as a reference for progressive disease the smallest measurement recorded since randomization) or the date of death, whichever occurred first. Data for participants who did not relapse or die were censored at the day of their last adequate tumor assessment. Duration of response was estimated by the Kaplan-Meier method.
Time frame: First Criteria Met for CR or PR to Measured PD or Death From Any Cause (Up to 40 Months)
Number of Participants With Adverse Events (AEs)
A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.
Time frame: Up To 41.7 Months
Pharmacokinetics (PK) Maximum Concentration (Cmax) Ramucirumab
Time frame: Cycle 1:Predose,1 hour(hr) post End of Infusion (EOI),48hr,72hr,168hr,336hr post-EOI;Cycle2:Predose,1hr post-EOI; Cycle3:Predose,1hr,48hr,72hr,168hr,336hr post-EOI; Cycle4:Predose,1hr post-EOI;Cycle6 and every other cycle thereafter:Predose,1hr Post EOI
PK: Minimum Concentration (Cmin) Ramucirumab
Time frame: Cycle 2:Predose,1hr post-EOI;Cycle3:Predose,1hr,48hr,72hr,168hr,336hr, post-EOI;Cycle4:Predose,1hr post-EOI;Cycle6:Predose,1hr Post EOI
PK: Cmax Icrucumab
Time frame: Cycle 1:Predose,1 hr post-EOI, 48hr, 72hr Post-EOI; Cycle 3:Predose,EOI,1.5hr,24hr,48hr,72hr,168hr Post EOI
PK: Cmin Icrucumab
Time frame: Cycle 2:Predose,1hr post-EOI;Cycle 3:Predose,EOI,1.5hr,24hr,48hr,72hr,168hr Post EOI
Number of Participants With Serum Anti-Ramucirumab Antibody Assessment
Number of participants with at least one positive titer treatment emergent antibody positive neutralizing antibody detecting. A sample will be considered positive for anti-Ramucirumab antibodies if it exhibits a post-baseline antibody level exceeding the normal anti-Ramucirumab antibody level seen in healthy untreated individuals.
Time frame: Cycle 1:Predose,EOI,1hr,48hr,72hr,168hr,336 hr post-EOI:Cycle 2:Predose,1hr post-EOI;Cycle 3:Predose,1hr,48hr,72hr,168hr,336hr post-EOI;Cycle 4:Predose,1hr post-EOI;Cycle 6:Predose,1hr post-EOI
Number of Participants With Serum Anti-Icrucumab Antibody Assessment
A sample will be considered positive for anti-Icrucumab antibodies if it exhibits a post-baseline antibody level exceeding the normal anti-IMC-Icrucumab antibody level seen in healthy untreated individuals.
Time frame: Cycle 1 Day 1 and Day 8 Predose and 1hr Post Dose
Pharmacodynamics (PD): Change in Circulating Levels of Placental Growth Factor (PlGF)
Time frame: 40 months
PD: Change in Circulating Levels of Vascular Endothelial Growth Factor-A (VEGF-A)
Time frame: 40 months
PD: Change in Circulating Levels of Vascular Endothelial Growth Factor-B (VEGF-B)
Time frame: 40 months
PD: Change in Circulating Levels of Soluble Vascular Endothelial Growth Factor-1 (VEGFR-1)
Time frame: 40 months
PD: Change in Circulating Levels of Soluble Vascular Endothelial Growth Factor-2 (VEGFR-2)
Time frame: 40 months
| Milestone | Docetaxel | Docetaxel + Ramucirumab DP | Docetaxel + Icrucumab |
|---|---|---|---|
| Started | 49 | 49 | 50 |
| Received at least 1 dose of study drug | 45 | 46 | 49 |
| Completed | 41 | 45 | 46 |
| Not completed | 8 | 4 | 4 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 6 | 2 | 3 |
| Withdrew: Never treated "death" | 0 | 1 | 0 |
| Withdrew: Never treated "pd" | 0 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
| Withdrew: Physician decision | 1 | 0 | 0 |
PFS time was the time from randomization until the date of objectively determined progressive disease (PD) or death due to any cause, whichever occurred first. According to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), PD was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the 20% relative increase, the sum must have also demonstrated an absolute increase of at least 5 millimeters (mm). The appearance of 1 or more new lesions and/or unequivocal progression of existing nontarget lesions was also considered progression. Participants without objectively determined PD who were alive at the end of the follow-up period (or lost to follow-up) were censored on the date of the participant's last complete radiographic tumor assessment; if no baseline or post-baseline radiologic assessment was available, the participant was censored at the date of randomization.
| months | Docetaxel | Docetaxel + Ramucirumab DP | Docetaxel + Icrucumab |
|---|---|---|---|
| Progression-Free Survival (PFS) | 2.8 (1.9 to 3.6) | 5.4 (3.1 to 6.9) | 1.6 (1.4 to 5.4) |
Participants achieved an objective response if they had a best overall response of partial response (PR) or complete response (CR). According to RECIST v1.1, PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter; CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \<10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels \[if tumor markers were initially above the upper limit of normal (ULN)\]. The percentage of participants who achieved an objective response=(number of participants with CR or PR)/(number of participants assessed)\*100.
| percentage of participants | Docetaxel | Docetaxel + Ramucirumab DP | Docetaxel + Icrucumab |
|---|---|---|---|
| Percentage of Participants Achieving Objective Response Rate (ORR) | 8.9 (2.5 to 21.2) | 23.9 (12.6 to 38.8) | 12.2 (4.6 to 24.8) |
The duration of response was measured from the time measurement criteria were first met for a CR or PR (whichever was first recorded) until the first date of objectively documented progressive disease (taking as a reference for progressive disease the smallest measurement recorded since randomization) or the date of death, whichever occurred first. Data for participants who did not relapse or die were censored at the day of their last adequate tumor assessment. Duration of response was estimated by the Kaplan-Meier method.
| months | Docetaxel | Docetaxel + Ramucirumab DP | Docetaxel + Icrucumab |
|---|---|---|---|
| Duration of Response | 4.6 (2.6 to 5.6) | 4.6 (0.7 to 7.0) | NA (2.9 to NA) |
A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.
| Participants | Docetaxel | Docetaxel + Ramucirumab DP | Docetaxel + Icrucumab |
|---|---|---|---|
| Any AE | 45 | 46 | 49 |
| Any SAE | 19 | 25 | 22 |
| microgram/milliliter (ug/mL) | Docetaxel + Ramucirumab DP |
|---|---|
| Cycle 1 | 258 ± 27 |
| Cycle 2 | 304 ± 31 |
| Cycle 3 | 300 ± 13 |
| Cycle 4 | 279 ± 40 |
| Cycle 6 | 252 ± 57 |
| microgram/milliliter (ug/mL) | Docetaxel + Ramucirumab DP |
|---|---|
| Cycle 2 | 19.5 ± 56 |
| Cycle 3 | 39.9 ± 34 |
| Cycle 4 | 35.3 ± 60 |
| Cycle 6 | 31.2 ± 61 |
| ug/mL | Docetaxel + Icrucumab |
|---|---|
| Cycle 1 Cmax | 474 ± 45 |
| Cycle 3 Cmax | 599 ± 27 |
| ug/mL | Docetaxel + Icrucumab |
|---|---|
| Day 1 Cycle 2 | NA ± NA |
| Day 1 Cycle 3 | 153 ± 66 |
Number of participants with at least one positive titer treatment emergent antibody positive neutralizing antibody detecting. A sample will be considered positive for anti-Ramucirumab antibodies if it exhibits a post-baseline antibody level exceeding the normal anti-Ramucirumab antibody level seen in healthy untreated individuals.
| Participants | Docetaxel + Ramucirumab DP |
|---|---|
| Number of Participants With Serum Anti-Ramucirumab Antibody Assessment | 1 |
A sample will be considered positive for anti-Icrucumab antibodies if it exhibits a post-baseline antibody level exceeding the normal anti-IMC-Icrucumab antibody level seen in healthy untreated individuals.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Docetaxel | — | 19/45 (42.2%) | 45/45 (100%) |
| Docetaxel + Ramucirumab DP | — | 25/46 (54.3%) | 46/46 (100%) |
| Docetaxel + Icrucumab | — | 22/49 (44.9%) | 49/49 (100%) |
| Event | Docetaxel | Docetaxel + Ramucirumab DP | Docetaxel + Icrucumab |
|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 5/45 | 9/46 | 3/49 |
| NeutropeniaBlood and lymphatic system disorders | 2/45 | 4/46 | 2/49 |
| PneumoniaInfections and infestations | 1/45 | 4/46 | 1/49 |
| SepsisInfections and infestations | 2/45 | 4/46 | 0/49 |
| Small intestinal obstructionGastrointestinal disorders | 1/45 | 3/46 | 1/49 |
| PyrexiaGeneral disorders | 0/45 | 3/46 | 0/49 |
| Urinary tract infectionInfections and infestations | 1/45 | 3/46 | 3/49 |
| AnaemiaBlood and lymphatic system disorders | 2/45 | 1/46 | 2/49 |
| DehydrationMetabolism and nutrition disorders | 2/45 | 1/46 | 2/49 |
| HaematuriaRenal and urinary disorders | 2/45 | 2/46 | 1/49 |
| Event | Docetaxel | Docetaxel + Ramucirumab DP | Docetaxel + Icrucumab |
|---|---|---|---|
| FatigueGeneral disorders | 36/45 | 38/46 | 38/49 |
| AlopeciaSkin and subcutaneous tissue disorders | 22/45 | 27/46 | 26/49 |
| Decreased appetiteMetabolism and nutrition disorders | 19/45 | 26/46 | 25/49 |
| DiarrhoeaGastrointestinal disorders | 11/45 | 25/46 | 22/49 |
| NauseaGastrointestinal disorders | 12/45 | 24/46 | 24/49 |
| Oedema peripheralGeneral disorders | 9/45 | 17/46 | 24/49 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 4/45 | 20/46 | 0/49 |
| AnaemiaBlood and lymphatic system disorders | 10/45 | 11/46 | 20/49 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/45 | 18/46 | 16/49 |
| DysgeusiaNervous system disorders | 17/45 | 14/46 | 16/49 |
All randomized participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Docetaxel | Docetaxel + Ramucirumab DP | Docetaxel + Icrucumab | Total |
|---|---|---|---|---|
| Mean | 66.6 ± 11.45 | 66.7 ± 9.06 | 64.1 ± 10.38 | 65.7 ± 10.33 |
| Sex: Female, Male(Participants) | Docetaxel | Docetaxel + Ramucirumab DP | Docetaxel + Icrucumab | Total |
|---|---|---|---|---|
| Female | 10 | 9 | 11 | 30 |
| Male | 35 | 37 | 38 | 110 |
| Ethnicity (NIH/OMB)(Participants) | Docetaxel | Docetaxel + Ramucirumab DP | Docetaxel + Icrucumab | Total |
|---|---|---|---|---|
| Hispanic or Latino | 4 | 3 | 2 | 9 |
| Not Hispanic or Latino | 41 | 43 | 47 | 131 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Docetaxel | Docetaxel + Ramucirumab DP | Docetaxel + Icrucumab | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 5 | 2 | 4 | 11 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 2 | 4 |
| White | 36 | 43 | 42 | 121 |
| More than one race | 2 | 1 | 1 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Docetaxel | Docetaxel + Ramucirumab DP | Docetaxel + Icrucumab | Total |
|---|---|---|---|---|
| Canada | 30 | 28 | 37 | 95 |
| United States | 15 | 18 | 12 | 45 |
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
The record gives a start of Apr 2011, a primary completion of Feb 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2019, 4 years 5 months after primary completion. A results delay was requested in May 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ramucirumab · Icrucumab